These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
81 related items for PubMed ID: 15233807
1. Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction. Wong W, Tolkoff-Rubin N, Delmonico FL, Cardarelli F, Saidman SL, Farrell ML, Shih V, Winkelmayer WC, Cosimi AB, Pascual M. Clin Transplant; 2004 Aug; 18(4):341-8. PubMed ID: 15233807 [Abstract] [Full Text] [Related]
2. A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Pascual M, Curtis J, Delmonico FL, Farrell ML, Williams WW, Kalil R, Jones P, Cosimi AB, Tolkoff-Rubin N. Transplantation; 2003 May 15; 75(9):1501-5. PubMed ID: 12792504 [Abstract] [Full Text] [Related]
3. Long-term outcomes after cyclosporine or mycophenolate withdrawal in kidney transplantation - results from an aborted trial. Åsberg A, Apeland T, Reisaeter AV, Foss A, Leivestad T, Heldal K, Thorud LO, Eriksen BO, Hartmann A, NILS Study Group. Clin Transplant; 2013 May 15; 27(2):E151-6. PubMed ID: 23351013 [Abstract] [Full Text] [Related]
4. Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine. Aleksic I, Baryalei M, Busch T, Pieske B, Schorn B, Strauch J, Sîrbu H, Dalichau H. Transplantation; 2000 Apr 27; 69(8):1586-90. PubMed ID: 10836367 [Abstract] [Full Text] [Related]
5. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. Hazzan M, Labalette M, Copin MC, Glowacki F, Provôt F, Pruv FR, Noël C. J Am Soc Nephrol; 2005 Aug 27; 16(8):2509-16. PubMed ID: 15987748 [Abstract] [Full Text] [Related]
6. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group. Gruessner RW. Clin Transplant; 1997 Aug 27; 11(4):299-312. PubMed ID: 9267719 [Abstract] [Full Text] [Related]
7. Conversion to mycophenolate mofetil in conjunction with stepwise withdrawal of cyclosporine in stable renal transplant recipients. Schrama YC, Joles JA, van Tol A, Boer P, Koomans HA, Hené RJ. Transplantation; 2000 Feb 15; 69(3):376-83. PubMed ID: 10706046 [Abstract] [Full Text] [Related]
8. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction. Smak Gregoor PJ, van Gelder T, van Besouw NM, van der Mast BJ, IJzermans JN, Weimar W. Transplantation; 2000 Jul 15; 70(1):143-8. PubMed ID: 10919591 [Abstract] [Full Text] [Related]
13. Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction. Cantarovich M, Tzimas GN, Barkun J, Deschênes M, Alpert E, Tchervenkov J. Transplantation; 2003 Jul 15; 76(1):98-102. PubMed ID: 12865793 [Abstract] [Full Text] [Related]
14. Cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversion. Thervet E, Morelon E, Ducloux D, Bererhi L, Noël LH, Janin A, Bedrossian J, Puget S, Chalopin JM, Mihatsch M, Legendre C, Kreis H. Clin Transplant; 2000 Dec 15; 14(6):561-6. PubMed ID: 11127309 [Abstract] [Full Text] [Related]
15. Effect of oral fructose load on serum uric acid and lipids in kidney transplant recipients treated with cyclosporine or tacrolimus. Zawiasa A, Szklarek-Kubicka M, Fijałkowska-Morawska J, Nowak D, Rysz J, Mamełka B, Nowicki M. Transplant Proc; 2009 Dec 15; 41(1):188-91. PubMed ID: 19249511 [Abstract] [Full Text] [Related]
16. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Hueso M, Bover J, Serón D, Gil-Vernet S, Sabaté I, Fulladosa X, Ramos R, Coll O, Alsina J, Grinyó JM. Transplantation; 1998 Dec 27; 66(12):1727-31. PubMed ID: 9884267 [Abstract] [Full Text] [Related]
18. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Asberg A, Midtvedt K, Line PD, Narverud J, Holdaas H, Jenssen T, Reisaeter AV, Johnsen LF, Fauchald P, Hartmann A. Transplantation; 2006 Jul 15; 82(1):62-8. PubMed ID: 16861943 [Abstract] [Full Text] [Related]
19. Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up. Ducloux D, Motte G, Billerey C, Bresson-Vautrin C, Vautrin P, Rebibou JM, Saint-Hillier Y, Chalopin JM. Transpl Int; 2002 Sep 15; 15(8):387-92. PubMed ID: 12221456 [Abstract] [Full Text] [Related]
20. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients. Kato Y, Tojimbara T, Iwadoh K, Koyama I, Nanmoku K, Kai K, Sannomiya A, Nakajima I, Fuchinoue S, Teraoka S. Int Immunopharmacol; 2006 Dec 20; 6(13-14):1984-92. PubMed ID: 17161352 [Abstract] [Full Text] [Related] Page: [Next] [New Search]